Pharmacological Mechanisms of Therapeutics: Parathyroid Hormone

Principles of Bone Biology, Two-Volume Set

Volumn 2, Issue , 2008, Pages 1659-1695

  Hanley, David A ^a   Watson, Patricia H ^b   Hodsman, Anthony B ^b   Dempster, David W ^c,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c HELEN HAYES HOSPITAL   (United States)

^d Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882467756     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00085-9     Document Type: Chapter

References (277)

1. Adami S., San Martin J., Munoz-Torres M., Econs M.J., Xie L., Dalsky G.P., McClung M., Felsenberg D., Brown J.P., Brandi M.L., Sipos A. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos. Int. 2008, 19:87-94.
2. Akhter M.P., Kimmel D.B., Recker R.R. Effect of parathyroid hormone (hPTH[1-84]) treatment on bone mass and strength in ovariectomized rats. J. Clin. Densitom. 2001, 4:13-23.
3. Akhter M.P., Fan Z., Rho J.Y. Bone intrinsic material properties in three inbred mouse strains. Calcif. Tissue Int. 2004, 75:416-420.
4. Akhter M.P., Otero J.K., Iwaniec U.T., Cullen D.M., Haynatzki G.R., Recker R.R. Differences in vertebral structure and strength of inbred female mouse strains. J. Musculoskelet. Neuronal. Interact. 2004, 4:33-40.
5. Alexander J.M., Bab I., Fish S., Muller R., Uchiyama T., Gronowicz G., Nahounou M., Zhao Q., White D.W., Chorev M., Gazit D., Rosenblatt M. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J. Bone Miner. Res. 2001, 16:1665-1673.
6. Alkhiary Y.M., Gerstenfeld L.C., Krall E., Westmore M., Sato M., Mitlak B.H., Einhorn T.A. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J. Bone Joint Surg. Am. 2005, 87:731-741.
7. Allen M.R., Burr D.B. Parathyroid hormone and bone biomechanics. Clin.Rev. Bone Miner. Metab. 2006, 4:259-268.
8. Andreassen T.T., Willick G.E., Morley P., Whitfield J.F. Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif. Tissue Int. 2004, 74:351-356.
9. Antoniucci D.M., Sellmeyer D.E., Bilezikian J.P., Palermo L., Ensrud K.E., Greenspan S.L., Black D.M. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J. Clin. Endocrinol. Metab. 2007, 92:942-947.
10. Baumann B.D., Wronski T.J. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 1995, 16:247-253.
11. Beamer W.G., Donahue L.R., Rosen C.J. Genetics and bone. Using the mouse to understand man. J. Musculoskelet. Neuronal. Interact. 2002, 2:225-231.
12. Bilezikian J.P., Marcus R., Levine M.A. The Parathyroids: basic and clinical concepts 1994, Raven Press, New York.
13. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
14. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., Garnero P., Bouxsein M.L., Bilezikian J.P., Rosen C.J. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 2003, 349:1207-1215.
15. Black D.M., Bilezikian J.P., Ensrud K.E., Greenspan S.L., Palermo L., Hue T., Lang T.F., McGowan J.A., Rosen C.J. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. 2005, 353:555-565.
16. Boden S.D., Kaplan F.S. Calcium homeostasis. Orthop. Clin. North Am. 1990, 21:31-42.
17. Bodine P.V., Seestaller-Wehr L., Kharode Y.P., Bex F.J., Komm B.S. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J. Cell Physiol. 2007, 210:352-357.
18. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
19. Boonen S., Marin F., Obermayer-Pietsch B., Simoes M.E., Barker C., Glass E.V., Hadji P., Lyritis G., Oertel H., Nickelsen T., McCloskey E.V. Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 2008, 93:852-860. Published online 26 Dec 2007 [Epub ahead of print].
20. Bouxsein M.L., Uchiyama T., Rosen C.J., Shultz K.L., Donahue L.R., Turner C.H., Sen S., Churchill G.A., Muller R., Beamer W.G. Mapping quantitative trait loci for vertebral trabecular bone volume fraction and microarchitecture in mice. J. Bone Miner. Res. 2004, 19:587-599.
21. Bouxsein M.L., Myers K.S., Shultz K.L., Donahue L.R., Rosen C.J., Beamer W.G. Ovariectomy-induced bone loss varies among inbred strains of mice. J. Bone Miner. Res. 2005, 20:1085-1092.
22. Bouxsein M.L., Pierroz D.D., Glatt V., Goddard D.S., Cavat F., Rizzoli R., Ferrari S.L. beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J. Bone Miner. Res. 2005, 20:635-643.
23. Brabant G., Prank K., Schofl C. Pulsatile patterns in hormone secretion. Trends Endocrinol. Metab, 1992, 3:183-190.
24. Bradbeer J.N., Arlot M.E., Meunier P.J., Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin. Endocrinol. 1992, 37:282-289.
25. Brommage R., Hotchkiss C.E., Lees C.J., Stancill M.W., Hock J.M., Jerome C.P. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J. Clin. Endocrinol. Metab. 1999, 84:3757-3763.
26. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., Hock J.M. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 2001, 16:157-165.
27. Canalis E., McCarthy T.L., Centrella M. Growth factors and cytokines in bone cell metabolism. Annu. Rev. Med. 1991, 42:17-24.
28. Canalis E. Skeletal growth factors. Osteoporosis 1996, 238-266. Academic Press, San Diego. R. Marcus, D. Feldman, J. Kelsey (Eds.).
29. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 2007, 357:905-916.
30. Cauley J.A., Robbins J., Chen Z., Cummings S.R., Jackson R.D., LaCroix A.Z., LeBoff M., Lewis C.E., McGowan J., Neuner J., Pettinger M., Stefanick M.L., Wactawski-Wende J., Watts N.B. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003, 290:1729-1738.
31. Chavassieux P.M., Arlot M.E., Meunier P.J. Intersample variation in bone histomorphometry: Comparison between parameter values measured on two contiguous transiliac bone biopsies. Calcif. Tissue Int. 1985, 37:345-350.
32. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodelling in patients with osteoporosis. J. Clin. Invest. 1997, 100:1475-1480.
33. Cheng P.T., Chan C., Muller K. Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate. J. Bone Miner. Res. 1995, 10:119-126.
34. Chesnut C.H., Silverman S., Andriano K., Genant H., Gimona A., Harris S., Kiel D., LeBoff M., Maricic M., Miller P., Moniz C., Peacock M., Richardson P., Watts N., Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteo-porotic fractures study. Am. J. Med. 2000, 109:267-276.
35. Christiansen P., Steiniche T., Brixen K., Hessov I., Melsen F., Heickendorff L., Mosekilde L. Primary hyperparathyroidism: Short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone 1999, 25:237-244.
36. Chu N.N., Li X.N., Chen W.L., Xu H.R. Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. Pharmazie 2007, 62:869-871.
37. Compston J.E. Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure. Bone 2006, 40:1447-1452.
38. Cosman F., Shen V., Xie F., Seibel M., Ratcliffe A., Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Ann. Intern. Med. 1993, 118:337-343.
39. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., Lindsay R. Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 2001, 16:925-931.
40. Cosman F., Nieves J.W., Zion M., Barbuto N., Lindsay R. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos. Int. 2007, Published online 11 Oct 2007 [Epub ahead of print].
41. Cummings S.R., Black D.M., Nevitt M.C., Browner W., Cauley J., Ensrud K., Genant H.K., Palermo L., Scott J., Vogt T.M. Bone density at various sites for prediction of hip fractures. Lancet 1993, 341:72-75.
42. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., Vogt T., Wallace R., Yates J., LaCroix A.Z. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998, 280:2077-2082.
43. Dalle C.L., Giannini S. Bone microarchitecture as an important determinant of bone strength. J. Endocrinol. Invest. 2004, 27:99-105.
44. Davison K.S., Siminoski K., Adachi J.D., Hanley D.A., Goltzman D., Hodsman A.B., Josse R., Kaiser S., Olszynski W.P., Papaioannou A., Ste-Marie L.G., Kendler D.L., Tenenhouse A., Brown J.P. Bone strength: the whole is greater than the sum of its parts. Semin. Arthritis Rheum. 2006, 36:22-31.
45. Deal C., Omizo M., Schwartz E.N., Eriksen E.F., Cantor P., Wang J., Glass E.V., Myers S.L., Krege J.H. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 2005, 20:1905-1911.
46. Deftos L.J., Nolan J.J.H., Seely B.L., Clopton P.C., Cote G.J., Whitham C.L., Florek L.J., Christenson T.A., Hill M.R. Intrapulmonary drug delivery of bone-active peptides: Bioactivity of inhaled calcitonin approximates injected calcitonin. J. Bone Miner. Res. 1996, 11:S95.
47. Delmas P.D., Schlemmer A., Gineyts E., Riis B., Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J. Bone Miner. Res. 1991, 6:639-644.
48. Delmas P.D., Vergnaud P., Arlot M.E., Pastoureau P., Meunier P.J., Nilssen M.H.L. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by bisphosphonate tiludronate-Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodelling system?. Bone 1995, 16:603-610.
49. Delmas, P., Watts, N., Miller, P., Cahall, D., Bilezikian, J., and Lindsay, R. (2007). Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: The OPTAMISE Study. Program of the 29th Annual Meeting of the American Society for Bone and Mineral Research, Abstract 1092.
50. Demiralp B., Chen H.L., Koh A.J., Keller E.T., McCauley L.K. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 2002, 143:4038-4047.
51. Dempster D.W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr. Rev. 1993, 14:690-709.
52. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., Shane E., Plavetic K., Muller R., Bilezikian J., Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J. Bone Miner. Res. 2001, 16:1846-1853.
53. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats. Endocrinology 1995, 136:3624-3638.
54. Dobnig H., Sipos A., Jiang Y., Fahrleitner-Pammer A., Ste-Marie L.G., Gallagher J.C., Pavo I., Wang J., Eriksen E.F. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J. Clin. Endocrinol. Metab. 2005, 90:3970-3977.
55. Duan Y., Seeman E., Turner C.H. The biomechanical basis of vertebral body fragility in men and women. J. Bone Miner. Res. 2001, 16:2276-2283.
56. Duan Y., Turner C.H., Kim B.T., Seeman E. Sexual dimorphism in vertebral fragility is more the result of gender differences in age-related bone gain than bone loss. J. Bone Miner. Res. 2001, 16:2267-2275.
57. Dumble M., Gatza C., Tyner S., Venkatachalam S., Donehower L.A. Insights into aging obtained from p53 mutant mouse models. Ann. N. Y. Acad. Sci. 2004, 1019:171-177.
58. Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 2006, 22:61-66.
59. Ebeling P.R., Jones J.D., Burritt M.F., Duerson C.R., Lane A.W., Hassager C., Kumar R., Riggs B.L. Skeletal responsiveness to endogenous parathyroid hormone in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 1992, 75:1033-1038.
60. Ejersted C., Andreassen T.T., Oxlund H., Jorgensen P.H., Bak B., Haggblad J., Torring O., Nilsson M.H. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J. Bone Miner. Res. 1993, 8:1097-1101.
61. Eiken P., Kolthoff N., Pors Neilsen S. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996, 19:191S-s193S.
62. Ensrud K.E., Black D.M., Palermo L., Barrett-Connor E., Quandt S.A., Thompson D.E., Karpf D.B. Treatment with alendronate prevents fractures in women at high risk. Arch. Intern. Med. 1997, 157:2617-2624.
63. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestade J., Glüer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-Year randomized clinical trial. JAMA 1999, 282:637-645.
64. Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 2004, 19:745-751.
65. Finkelstein J.S., Klibanski A., Schaefer E.H., Hornstein M.D., Schiff I., Neer R.M. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N. Engl. J. Med. 1994, 331:1618-1623.
66. Finkelstein J.S., Klibanski A., Arnold A.L., Toth T.L., Hornstein M.D., Neer R.M. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34). JAMA 1998, 280:1067-1073.
67. Finkelstein J.S., Klibanski A., Arnold A.L., Toth T.L., Neer R.M. Prevention of estrogen deficiency related bone loss with human parathyroid hormone-(1-34): Randomized controlled trial. JAMA 1998, 280:1067-1076.
68. Finkelstein J.S., Arnold A.L. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J. Clin. Endocrinol. Metab. 1999, 84:1214-1219.
69. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 2003, 349:1216-1226.
70. Finkelstein J.S., Leder B.Z., Burnett S.M., Wyland J.J., Lee H., de la Paz A.V., Gibson K., Neer R.M. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J. Clin. Endocrinol. Metab. 2006, 91:2882-2887.
71. Fox J., Miller M.A., Recker R.R., Bare S.P., Smith S.Y., Moreau I. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J. Musculoskelet. Neuronal Interact. 2005, 5:356-357.
72. Fox J., Miller M.A., Newman M.K., Metcalfe A.F., Turner C.H., Recker R.R., Smith S.Y. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif. Tissue Int. 2006, 79:262-272.
73. Fox J., Miller M.A., Newman M.K., Turner C.H., Recker R.R., Smith S.Y. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J. Bone Miner. Res. 2007, 22:260-273.
74. Fraher L.J., Klein K., Marier R., Freeman D., Hendy G.N., Goltzman D., Hodsman A.B. Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. J. Clin. Endocrinol. Metab. 1995, 80:60-64.
75. Fraher L.J., Avram R., Watson P.H., Hendy G.N., Henderson J.E., Chong K.L., Goltzman D., Morley P., Willick G.E., Whitfield J.F., Hodsman A.B. Comparison of the biochemical responses to parathyroid hormone (hPTH)-(1-31) and hPTH(1-34) in healthy humans. J. Clin. Endocrinol. Metab. 1999, 84:2743-2749.
76. Frost H.M., Jee W.S.S. On the rat model of human osteopenias and osteoporoses. Bone Miner. 1992, 18:227-236.
77. Fujita T., Inoue T., Morii H., Morita R., Norimatsu H., Orimo H., Takahashi H.E., Yamamoto K., Fukunaga M. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: A randomized double-masked prospective study using three dose levels. Osteoporos Int. 1999, 9:306.
78. Fujita T., Inoue T., Morii H., Morita R., Norimatsu H., Orimo H., Takahashi H.E., Yamamoto K., Fukunaga M. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: A randomized double-masked prospective study using three dose levels. Osteoporos. Int. 1999, 9:296-306.
79. Gallagher J.C. PTHrP(1-34) analog, semparatide acetate (RS-66271), causes sustained increases in spine in postmenopausal osteoporotic women: Two randomized placebo-controlled trials. J. Bone Miner. Res. 1999, 14:S137.
80. Garn S.M. The Earlier Gain and the Later Loss of Cortical Bone In Nutritional 1970, perspective Charles C Thomas, Springfield, IL.
81. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 1994, 79(6):1693-1700.
82. Greenspan S.L., Bone H.G., Ettinger M.P., Hanley D.A., Lindsay R., Zanchetta J.R., Blosch C.M., Mathisen A.L., Morris S.A., Marriott T.B. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 2007, 146:326-339.
83. Grey A.B., Evans M.C., Stapleton J.P., Reid I.R. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Ann. Intern. Med. 1994, 121:745-749.
84. Gunness-Hey M., Hock J.M. Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone 1989, 10:447-452.
85. Harper K.D., Krege J.H., Marcus R., Mitlak B.H. Osteosarcoma and teriparatide?. J Bone Miner. Res. 2007, 22:334.
86. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., Chesnut C.H., Brown J., Eriksen E.F., Hoseyni M.S., Axelrod D.W., Miller P.D. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999, 282:1344-1352.
87. Henry J.G., Mitnick M.A., Stewart A.F. Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. J. Clin. Endocrinol. Metab. 1997, 82:900-906.
88. Hernandez C., Beaupre G.S., Marcus R., Carter D.R. A theoretical analysis of the contributions of remodelling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 2001, 29:511-516.
89. Hesch R.D., Heck J., Auf'mkolk B. First clinical observations with hPTH (1-38), a more potent human parathyroid hormone peptide. Horm. Metab. Res. 1984, 16:559-560.
90. Hesch R.D., Busch U., Prokop M., Delling G., Harms H.M., Rittinghaus E.F. Increase in bone mass and turnover in low turnover osteoporosis by combined (1-38) hPTH and Calcitonin nasal spray. Calcitonin 88: New Therapeutic Perspectives: The Nasal Spray 1989, 139-157. Sandos AG, Basle. G.F. Mazzuoli (Ed.).
91. Hesch R.D., Busch U., Prokop M., Delling G., Rittinghaus E.F. Increase of vertebral density by combination therapy with pulsatile 1-38 hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif. Tissue Int. 1989, 44:176-180.
92. Hesp R., Hulme P., Williams D., Reeve J. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1-34). Metab. Bone Dis. Relat. Res. 1981, 2:331-334.
93. Hirano T., Burr D.B., Cain R.L., Hock J.M. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif. Tissue Int. 2000, 66:456-460.
94. Hock J.M., Gera I., Fonesca J., Raisz L.G. Human parathyroid hormone (1-34) increases rat bone mass in ovariectomized and orchidectomized rats. Endocrinology 1988, 122:2899-2904.
95. Hodsman A.B., Fraher L.J. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. Bone Miner. 1990, 9:137-152.
96. Hodsman A.B., Steer B.M. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for novo bone formation on quiescent cancellous surfaces. Bone 1993, 14:523-527.
97. Hodsman A.B., Fraher L.J., Ostbye T., Adachi J.D., Steer B.M. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest. 1993, 91:1138-1148.
98. Hodsman A.B., Fraher L.J., Watson P.H., Ostbye T., Stitt L.W., Adachi J.D., Taves D.H., Drost D. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 1997, 82:620-628.
99. Hodsman A.B., Kisiel M., Adachi J.D., Fraher L.J., Watson P.H. Histomorphometric evidence for increased bone turnover in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 2000, 27:311-318.
100. Hodsman A.B., Steer B.M., Fraher L.J., Drost D.J. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone(1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 1991, 14:67-83.
101. Hodsman A.B., Hanley D.A., Ettinger M.P., Bolognese M.A., Fox J., Metcalfe A.J., Lindsay R. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2003, 88:5212-5520.
102. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., Kendler D.L., McClung M.R., Miller P.D., Olszynski W.P., Orwoll E., Yuen C.K. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 2005, 26:688-703.
103. Hodsman A., Papaioannou A., Cranney A. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 2006, 175:48.
104. Holzer G., Majeska R.J., Lundy M.W., Hartke J.R., Einhorn T.A. Parathyroid hormone enhances fracture healing. A preliminary report. Clin. Orthop. Relat. Res. 1999, Sep(366):258-263.
105. Hori M., Uzawa T., Morita K., Noda T., Takahashi H., Inoue J. Effect of human parathyroid hormone (PTH(1-34)) on experimental osteopenia of rats induced by ovariectomy. Bone Miner. 1988, 3:193-199.
106. Horwitz M.J., Tedesco M.B., Gundberg C., Garcia-Ocana A., Stewart A.F. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2003, 88:569-575.
107. Hurley M.M., Okada Y., Xiao L., Tanaka Y., Ito M., Okimoto N., Nakamura T., Rosen C.J., Doetschman T., Coffin J.D. Impaired bone anabolic response to parathyroid hormone in Fgf2-/- and Fgf2 +/? mice. Biochem. Biophys. Res. Commun. 2006, 341:989-994.
108. Iida-Klein A., Hughes C., Lu S.S., Moreno A., Shen V., Dempster D.W., Cosman F., Lindsay R. Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice. J. Bone Miner. Res. 2006, 21:274-282.
109. Iida-Klein A., Lu S.S., Cosman F., Lindsay R., Dempster D.W. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 2007, 40:391-398.
110. Ishizuya T., Yokose S., Hori M., Noda T., Suda T., Yoshiki S., Yamaguchi A. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 1997, 99:2961-2970.
111. Iwaniec U.T., Moore K., Rivera M.F., Myers S.E., Vanegas S.M., Wronski T.J. A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos. Int. 2007, 18:351-362.
112. Jerome C.P. Anabolic effect of high doses of human parathyroid hormone (1-38) in mature intact female rats. J. Bone Miner. Res. 1994, 9:933-942.
113. Jerome C.P., Johnson C.S., Vafai H.T., Kaplan K.C., Bailey J., Capwell B., Fraser F., Hansen L., Ramsay H., Shadoan M., Lees C.J., Thomsen J.S., Mosekilde L. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 1999, 25:301-309.
114. Jerome C.P., Burr D.B., Van Bibber T., Hock J.M., Brommage R. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 2001, 28:150-159.
115. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 2003, 18:1932-1941.
116. Johansson A.G., Rosen C.L. The insulin-like growth factors: Potential anabolic agents for the skeleton. Anabolic Treatments for Osteoporosis 1998, 185-205. CRC Press, Boca Raton, FL. J.E. Whitfield, P. Morley (Eds.).
117. Jolette J., Wilker C.E., Smith S.Y., Doyle N., Hardisty J.F., Metcalfe A.J., Marriott T.B., Fox J., Wells D.S. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol. Pathol. 2006, 34:929-940.
118. Jouishomme H., Whitfield J.F., Gagnon L., Maclean S., Isaacs R., Chakravarthy B., Durkin J., Neugebauer W., Willick G., Rixon R.H. Further definition of the protein kinase C activation domain of the parathyroid hormone. J. Bone Miner. Res. 1994, 9:943-949.
119. Kalu D.N. Evaluation of the pathogenesis of skeletal changes in ovariectomized rats. Endocrinology 1984, 115:507-512.
120. Kalu D.N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 1991, 15:175-192.
121. Kanis J.A., Melton L.J., Christiansen C., Johnston C.C., Khaltaev N. Perspective: The diagnosis of osteoporosis. J. Bone Miner. Res. 1994, 9:1137-1141.
122. Kaplan L., Katz A., Ben-Isaac C., Massry S. Malignant neoplasms and parathyroid adenoma. Cancer 1971, 28:401-407.
123. Kaufman J.M., Orwoll E., Goemaere S., San Martin J., Hossain A., Dalsky G.P., Lindsay R., Mitlak B.H. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 2005, 16:510-516.
124. Keaveny T.M., Donley D.W., Hoffmann P.F., Mitlak B.H., Glass E.V., San Martin J.A. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J. Bone Miner. Res. 2007, 22:149-157.
125. Kent G.N., Loveridge N., Reeve J., Zanelli J.M. Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. Clin. Sci. 1985, 68:171-177.
126. Khosla S., Melton L.J., Wermers R.A., Crowson C.S., O'Fallon W.M., Riggs B.L. Primary hyperparathyroidism and the risk of fracture: A population-based study. J. Bone Miner. Res. 1999, 14:1700-1707.
127. Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W.F., Moskowitz M.A. Hip fracture and the use of estrogens in postmenopausal women. N. Engl. J. Med. 1987, 317(19):1169-1174.
128. Kim C.H., Takai E., Zhou H., von Stechow D., Muller R., Dempster D.W., Guo X.E. Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J. Bone Miner. Res. 2003, 18:2116-2125.
129. Kimmel D.B., Bozzato R.P., Kronis K.A., Coble T., Sindrey D., Kwong P., Recker R.R. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993, 132(4):1577-1584.
130. Kitahara K., Ishijima M., Rittling S.R., Tsuji K., Kurosawa H., Nifuji A., Denhardt D.T., Noda M. Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 2003, 144:2132-2140.
131. Kleerekoper M., Peterson E.L., Nelson D.A., Phillips E., Schork M.A., Tilley B.C., Parfitt A.M. A randomized trail of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos. Int. 1991, 1:155-161.
132. Komarova S.V. Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone. Endocrinology 2005, 146:3589-3595.
133. Komatsubara S., Mori S., Mashiba T., Nonaka K., Seki A., Akiyama T., Miyamoto K., Cao Y., Manabe T., Norimatsu H. Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 2005, 36:678-687.
134. Koppler J.D., Massry S.G. Is there an association between neoplasia and primary or secondary hyperparathyroidism?. Am. J. Nephrol. 1988, 8:437-448.
135. Kumar S., Dare L., Vasko-Moser J.A., James I.E., Blake S.M., Rickard D.J., Hwang S.M., Tomaszek T., Yamashita D.S., Marquis R.W., Oh H., Jeong J.U., Veber D.F., Gowen M., Lark M.W., Stroup G. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007, 40:122-131.
136. Kurland E.S., Cosman F., McMahon D.J., Rosen C.J., Lindsay R., Bilezikian J.P. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. 2000, 85:3069-3076.
137. Lane N.E., Thompson J.M., Strewler G.J., Kinney J.H. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J. Bone Miner. Res. 1995, 10:1470-1477.
138. Lane N.E., Kimmel D.B., Nilsson M.H., Cohen F.E., Newton S., Nissenson R.A., Strewler G.J. Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model. J. Bone Miner. Res. 1996, 11:614-625.
139. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathryoid hormone treatment can reverse corticosteroid-induced osteoporosis. J. Clin. Invest. 1998, 102:1627-1633.
140. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 1998, 102:1627-1633.
141. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J. Bone Miner. Res. 2000, 15:944-951.
142. Lane N.E., Yao W., Kinney J.H., Modin G., Balooch M., Wronski T.J. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J. Bone Miner. Res. 2003, 18:2105-2115.
143. Leaffer D., Sweeney M., Kellerman L.A. Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34). Endocrinology 1995, 136:3624-3631.
144. Leupin O., Kramer I., Collette N.M., Loots G.G., Natt F., Kneissel M., Keller H. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 2007, 22:1957-1967.
145. Li M., Mosekilde L., Sogaard C.H., Thomsen J.S., Wronski T.J. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 1995, 16:629-635.
146. Li M., Liang H., Shen Y., Wronski T.J. Parathyroid hormone stimulates cancellous bone formation at skeletal sites regardless of marrow composition in ovariectomized rats. Bone 1999, 24:95-100.
147. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., Dequeker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C., Lombardi A., Shah R.V., Hirsch L.J., Karpf D.B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 1995, 333:1437-1443.
148. Lindsay R., Nieves J., Henneman E., Shen V., Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): Kinetics and biochemical response to estrogenized osteoporotic patients. J. Clin. Endocrinol. Metab. 1993, 77:1535-1539.
149. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., Dempster D. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
150. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami S., Mautalen C., Reginster J.Y., Stepan J.J., Myers S.L., Mitlak B.H. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 2004, 164:2024-2030.
151. Lindsay R., Cosman F., Zhou H., Bostrom M.P., Shen V.W., Cruz J.D., Nieves J.W., Dempster D.W. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J. Bone Miner. Res. 2006, 21:366-373.
152. Lindsay R., Zhou H., Cosman F., Nieves J., Dempster D.W., Hodsman A.B. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J. Bone Miner. Res. 2007, 22:495-502.
153. Liu C.C., Kalu D.N. Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J. Bone Miner. Res. 1990, 5:973-982.
154. Liu C.C., Kalu D.N., Salerno E., Echon R., Hollis B.W., Ray M. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J. Bone Miner. Res. 1991, 6:1071-1080.
155. Liu H., Michaud K., Nayak S., Karpf D.B., Owens D.K., Garber A.M. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch. Intern. Med. 2006, 166:1209-1217.
156. Locklin R.M., Khosla S., Turner R.T., Riggs B.L. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J. Cell Biochem. 2003, 89:180-190.
157. Lufkin E.G., Wahner H.W., O'Fallon W.M., Hodgson S.F., Kotowicz M.A., Lane A.W., Judd H.L., Caplan R.H., Riggs B.L. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med. 1992, 117:1-9.
158. Maissonneuve P., Agodoa L., Gellert R., Steart J.H., Buccianti G., Lowenfels A.B., Wolfe R.A., Jones E., Disney A.P., Briggs D., McCredie M., Boyle P. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999, 354:93-99.
159. Ma Y.L., Zeng Q., Donley D.W., Ste-Marie L.G., Gallagher J.C., Dalsky G.P., Marcus R., Eriksen E.F. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J. Bone Miner. Res. 2006, 21:855-864.
160. Marcus R., Villa M.L., Cheema M., Cheema C., Newhall K., Holloway L. Effects of conjugated estrogen on the calcitriol response to parathyroid hormone in postmenopausal women. J. Clin. Endocrinol. Metab. 1992, 74:413-418.
161. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br. Med. J. 1996, 312:1254-1259.
162. Mashiba T., Tanizawa T., Takano Y., Takahashi H.E., Mori S., Norimatsu H. A histomorphometric study on effects of single and concurrent intermittent administration of human PTH(1-34) and bisphosphonate cimadronate on tibial metaphysis in ovariectomized rats. Bone 1995, 17:273S-s278S.
163. Mashiba T., Burr D.B., Turner C.H., Sato M., Cain R.L., Hock J.M. Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001, 28:538-547.
164. Maxim P., Ettinger B., Spitalny G.M. Fracture protection provided by long-term estrogen treatment. Osteoporos. Int. 1995, 5:23-29.
165. McCarthy T.L., Centrella M., Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989, 124:1247-1253.
166. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., Adami S., Fogelman I., Diamond T., Eastell R., Meunier P.J., Reginster J.-Y. Effect of risedronate on hip fracture risk in elderly women. N. Engl. J. Med. 2001, 344:333-340.
167. McClung M.R., San Martin J., Miller P.D., Civitelli R., Bandeira F., Omizo M., Donley D.W., Dalsky G.P., Eriksen E.F. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 2005, 165:1762-1768.
168. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., Peacock M., Miller P.D., Lederman S.N., Chesnut C.H., Lain D., Kivitz A.J., Holloway D.L., Zhang C., Peterson M.C., Bekker P.J. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2006, 354:821-831.
169. McMurtry C.T., Schranck F.W., Walkenhorst D.A., Murphy W.A., Kocher D.B., Teitelbaum S.L., Rupich R.C., Whyte M.P. Significant developmental elevation in serum parathyroid hormone levels in a large kindred with familial benign (Hypocalciuric) hypercalcemia. Am. J. Med. 1992, 93:247-258.
170. McSheehy P.M., Chambers T.J. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 1986, 118:824-828.
171. Meng X.W., Liang X.G., Birchman R., Wu D.D., Dempster D.W., Lindsay R., Shen V. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J. Bone Miner. Res. 1996, 11:421-429.
172. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., Cannata J., Balogh A., Lemmel E.M., Pors-Nielsen S., Rizzoli R., Genant H.K., Reginster J.Y. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004, 350:459-468.
173. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., Cannata J., Balogh A., Lemmel E.M., Pors-Nielsen S., Rizzoli R., Genant H.K., Reginster J.Y. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004, 350:459-468.
174. Miao D., He B., Jiang Y., Kobayashi T., Soroceanu M.A., Zhao J., Su H., Tong X., Amizuka N., Gupta A., Genant H.K., Kronenberg H.M., Goltzman D., Karaplis A.C. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Invest. 2005, 115:2402-2411.
175. Miller P.D., Bilezikian J.P., Diaz-Curiel M., Chen P., Marin F., Krege J.H., Wong M., Marcus R. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J. Clin. Endocrinol. Metab. 2007, 92:3535-3541.
176. Moen M.D., Scott L.J. Recombinant full-length parathyroid hormone (1-84). Drugs 2006, 66:2371-2381. discussion 2382-2375.
177. Morley P., Whitfield J.F., Willick G.E. Anabolic effects of parathyroid hormone on bone. Trends Endocrinol. Metab. 1997, 8:225-231.
178. Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin. Drug Deliv. 2005, 2:993-1002.
179. Mosekilde L., Danielsen C.C., Gasser J. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology 1994, 134:2126-2134.
180. Mosekilde L., Sogaard C.H., McOsker J.E., Wronski T.J. PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate)-Assessed in sexually mature, ovariectomized rats. Bone 1994, 15:401-408.
181. Mosekilde L., Danielsen C.C., Sogaard C.H., McOsker J.E., Wronski T.J. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-Assessed in a sexually mature, ovariectomized rat model. Bone 1995, 16:223-230.
182. Naessen T., Persson I., Adami H.-O., Bergstrom R., Bergkvist L. Hormone replacement therapy and the risk for first hip fracture: A prospective, population-based cohort study. Ann. Intern. Med. 1990, 113:95-103.
183. Neer R.M., Slovik D.M., Doppelt S.H., Daly M., Rosenthal D.I., Lo K., Potts J.T. The use of parathyroid hormone plus 1,25-dihydroxyvitamin D to increase trabecular bone in osteoporotic men and postmenopausal women. Osteoporosis 1987 1987, 835-929. Osteopress Aps, Copenhagen. C. Christiansen, J.S. Johansen, B.J. Riis (Eds.).
184. Neer R.M., Slovik D.M., Daly M., Lo K., Potts J.T., Nussbaum S.R. Treatment of post-menopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporosis 1991, Osteopress APS, Copenhagen. C. Christiansen, K. Overgaard (Eds.).
185. Neer R., Slovik D.M., Daly M., Potts J.T., Nussbaum S.R. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos. Int. 1993, 3:204-205.
186. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.-Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitlak B.H. Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N. Engl. J. Med. 2001, 344:1434-1441.
187. Neugebauer W., Barbier J.R., Sung W.L., Whitfield J.F., Willick G.E. Solution structure and adenylyl cyclase stimulating activities of C-terminal truncated human parathyroid hormone analogues. Biochemistry 1995, 34:8835-8842.
188. Nomura M., Okuno T., Yanagawa A., Kono T. Studies on intranasal absorption of new formulation of 1-34 PTH in healthy volunteers. Osteoporosis. Int. 1996, 6. Abstr PTu746, 269.
189. Nozaka K., Miyakoshi N., Kasukawa Y., Maekawa S., Noguchi H., Shimada Y. Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 2008, 42:90-97.
190. Onyia J.E., Helvering L.M., Gelbert L., Wei T., Huang S., Chen P., Dow E.R., Maran A., Zhang M., Lotinun S., Lin X., Halladay D.L., Miles R.R., Kulkarni N.H., Ambrose E.M., Ma Y.L., Frolik C.A., Sato M., Bryant H.U., Turner R.T. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J. Cell Biochem. 2005, 95:403-418.
191. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., Kaufman J.M., Clancy A.D., Gaich G.A. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res 2003, 18:9-17.
192. Parfitt A.M. The actions of parathyroid hormone on bone: Relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part 3: PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism. Metabolism 1976, 25:1033-1069.
193. Parfitt A.M. Morphologic basis of bone mineral measurements: Transient and steady state effects of treatment in osteoporosis. Miner. Electrolyte Metab. 1980, 4:273-287.
194. Parfitt A.M. Use of bisphosphonates in the prevention of bone loss and fractures. Am. J. Med. 1991, 91(Suppl 5B):S42-sS46.
195. Parisien M., Cosman F., Mellish R.W.E., Schnitzer M., Nieves J., Silver-berg S.J., Shane E., Kimmel D., Recker R.R., Bilezikian J.P., Lindsay R., Dempster D.W. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J. Bone Miner. Res. 1995, 10:1393-1399.
196. Patton J.S., Trinchero P., Platz R.M. Bioavailability of pulmonary delivered peptides and proteins: ?-Interferon, calcitonins and parathyroid hormones. J. Controlled Release, 1994, 28:79-85.
197. Pehue M., Policard A., Dufort A. L'Osteoporose ou maladie des os marmoreens. Press Med. 1931, 53:999.
198. Pfutzner A., Flacke F., Pohl R., Linkie D., Engelbach M., Woods R., Forst T., Beyer J., Steiner S.S. Pilot study with technosphere/PTH(1-34)-a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Horm. Metab. Res. 2003, 35:319-323.
199. Pickard B.W., Hodsman A.B., Fraher L.J., Watson P.H. Type 1 parathyroid hormone receptor (PTH1R) nuclear trafficking: regulation of PTH1R nuclear-cytoplasmic shuttling by importin-alpha/beta and chromosomal region maintenance 1/exportin 1. Endocrinology 2007, 148:2282-2289.
200. Pierroz D.D., Bouxsein M.L., Rizzoli R., Ferrari S.L. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 2006, 39:260-267.
201. Plotkin H., Gundberg C., Mitnick M., Stewart A.F. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: Potential as an anabolic therapy for osteoporosis. J. Clin. Endocrinol. Metab. 1998, 83:2786-2791.
202. Pogoda P., Priemel M., Schilling A.F., Gebauer M., Catala-Lehnen P., Barvencik F., Beil F.T., Munch C., Rupprecht M., Muldner C., Rueger J.M., Schinke T., Amling M. Mouse models in skeletal physiology and osteoporosis: Experiences and data on 14,839 cases from the Hamburg Mouse Archives. J. Bone Miner. Metab. 2005, 23(Suppl):97-102.
203. Potter L.K., Greller L.D., Cho C.R., Nuttall M.E., Stroup G.B., Suva L.J., Tobin F.L. Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics. Bone 2005, 37:159-169.
204. Qi H., Li M., Wronski T.J. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J. Bone Miner. Res. 1995, 10:948-955.
205. Radulescu R.T. Insulin receptor a-subunit: A putative gene regulatory molecule. Med. Hypotheses 1995, 45:107-111.
206. Reeve J., Arlot M., Bernat M., Charhon S., Edouard C., Slovik D., Vismans F.J.F.E., Meunier P.J. Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: The influence of human parathyroid (hPTH 1-34) therapy. Metab. Bone Dis. Relat. Res. 1981, 3:23-30.
207. Reeve J., Arlot M., Bernat M., Edouard C., Hesp R., Slovik D., Vismans F.J.F.E., Meunier P.J. Treatment of osteoporosis with human parathyroid fragment 1-34: A positive final tissue balance in trabecular bone. Metab. Bone Dis. Relat. Res. 1980, 2:355-360.
208. Reeve J., Arlot M.E., Bradbeer J.N., Hesp R., Mcally E., Meunier P.J., Zanelli J.M. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporos. Int 1993, 3(Suppl 1):S199-sS203.
209. Reeve J., Arlot M., Price T.R., Edouard C., Hesp R., Hulme P., Ashley J.P., Zanelli J.M., Green J.R., Tellez M., Katz D., Spinks T.J., Meunier P.J. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis. Eur. J. Clin. Invest. 1987, 17:421-428.
210. Reeve J., Bradbeer J.N., Arlot M., Davies U.M., Green J.R., Hampton L., Edouard C., Hesp R., Hulme P., Ashby J.P., Zanelli J.M., Meunier P.J. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteoporos. Int. 1991, 1:162-170.
211. Reeve J., Davies U.M., Hesp R., McNally E., Katz D. Treatment of osteoporosis with human parathyroid peptide and observations on the effect of sodium fluoride. Br. Med. J. 1990, 301:314-318.
212. Reeve J., Hesp R., Williams D., Klenerman L., Zanelli J.M., Darby A.J., Tregear G.W., Parsons J.A., Hume R. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976, 1:1035-1038.
213. Reeve J., Meunier P.J., Parsons J.A., Bernat M., Bijvoet O.L.M., Courpron P., Edouard C., Klenerman L., Neer R.M., Renier J.C., Slovik D., Vismans F.J.F.E., Potts J.T. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. Br. Med. J. 1980, 280:1340-1344.
214. Reeve J., Tregear G.W., Parsons J.A. Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis. Clin. Endocrinol. 1976, 21:469-477.
215. Reginster J.-Y., Minne H.W., Sorenson O.H., Hooper M., Roux C., Brandi M.L., Lund B., Ethgen D., Pack S., Roumagnac I., East-ell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. 2000, 11:83-91.
216. Riggs B.L., Seeman E., Hodgson S.F., Taves D.R., O'Fallon W.M. Effects of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. N. Engl. J. Med. 1982, 306:446-450.
217. Riggs B.L., Hodgson S.F., O'Fallon W.M., Chao E.Y.S., Wahner H.W., Muhs J.M., Cedel S.L., Melton L. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N. Engl. J. Med. 1990, 322:802-809.
218. Riggs B.L., Melton L.J. Drug therapy: The prevention and treatment of osteoporosis. N. Engl. J. Med. 1992, 327:620-627.
219. Riis B.J., Overgaard K., Christiansen C. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporos. Int. 1995, 5:276-280.
220. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., Rosen C.J. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 2000, 85:2129-2134.
221. Rixon R.H., Whitfield J.F., Gagnon L., Isaacs R.J., Maclean S., Chackravarthy B., Durkin J.P., Neugebauer W., Ross V., Sung W., Willick G.E. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylate cyclase. J. Bone Miner. Res. 1994, 9:1179-1189.
222. Roe E.B., Sanchez S., Cann C.E., del Puerto G.A., Pierini E., Arnaud C.D. PTH-induced increases in bone density are preserved with estrogen: Results from a follow-up year in postmenopausal osteoporosis. J. Bone Miner. Res. 2000, 15:S193.
223. Roe E.B., Sanchez S.D., del Puerto G.A., Pierini E., Bacchetti P., Cann C.E., Arnaud C.D. Parathyroid hormone 1-34 (hPTH1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis-results from a placebo-controlled randomized trial. J. Bone Miner. Res. 1999, 14:S137.
224. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzi P., Klaushofer K. Alendronate increases the degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2003, 29:185-191.
225. Rosen C.J., Churchill G.A., Donahue L.R., Shultz K.L., Burgess J.K., Powell D.R., Ackert C., Beamer W.G. Mapping quantitative trait loci for serum insulin-like growth factor-1 levels in mice. Bone 2000, 27:521-528.
226. Rosen C.J., Ackert-Bicknell C.L., Adamo M.L., Shultz K.L., Rubin J., Donahue L.R., Horton L.G., Delahunty K.M., Beamer W.G., Sipos J., Clemmons D., Nelson T., Bouxsein M.L., Horowitz M. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 2004, 35:1046-1058.
227. Ross P.D., Wasnich R.D., Davis J.W. Fracture prediction models for osteoporosis prevention. Bone 1990, 11:327-331.
228. Ross P.D., Davis J.W., Epstein R.S., Wasnich R.D. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann. Intern. Med. 1991, 114:919-923.
229. Rozen N., Lewinson D., Bick T., Jacob Z.C., Stein H., Soudry M. Fracture repair: modulation of fracture-callus and mechanical properties by sequential application of IL-6 following PTH 1-34 or PTH 28-48. Bone 2007, 41:437-445.
230. Samadfam R., Xia Q., Goltzman D. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 2007, 148:2778-2787.
231. Sato M., Westmore M., Ma Y.L., Schmidt A., Zeng Q.Q., Glass E.V., Vahle J., Brommage R., Jerome C.P., Turner C.H. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J. Bone Miner. Res. 2004, 19:623-629.
232. Sawakami K., Robling A.G., Ai M., Pitner N.D., Liu D., Warden S.J., Li J., Maye P., Rowe D.W., Duncan R.L., Warman M.L., Turner C.H. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J. Biol. Chem. 2006, 281:23698-23711.
233. Schweitert H.R., Groen E.W.J., Sollie F.A.E., Jonkman J.H.G. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-80)] in healthy postmenopausal volunteers. Clin. Pharmacol. Ther. 1997, 61:360-376.
234. Seeman E., Delmas P.D. Bone quality--the material and structural basis of bone strength and fragility. N. Engl. J. Med. 2006, 354:2250-2261.
235. Sellmeyer D.E., Black D.M., Palermo L., Greenspan S., Ensrud K., Bilezikian J., Rosen C.J. Heterogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos. Int. 2007, 18:973-979.
236. Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932, 16:547-558.
237. Shen V., Dempster D.W., Birchman R., Xu R., Lindsay R. Loss of cancellous bone mass and connectivity in ovariectomizd rats can be restored by combined treatment with parathyroid hormone and estradiol. J. Clin. Invest. 1993, 91:2479-2487.
238. Shen V., Dempster D.W., Mellish R.W.E., Birchman R., Horbert W., Lindsay R. Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1-34) and 17-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif. Tissue Int. 1992, 50:214-220.
239. Shen V., Birchman R., Xu R., Otter M., Wu D., Lindsay R., Dempster D.W. Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. J. Clin. Invest. 1995, 96:2331-2338.
240. Shen V., Birchman R., Liang X.G., Wu D.D., Dempster D.W., Lindsay R. Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats. J. Bone Miner. Res. 1998, 13:883-890.
241. Shen V., Birchman R., Wu D.D., Lindsay R. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion. J Bone Miner Res 2000, 15:740-746.
242. Sibonga J.D., Iwaniec U.T., Shogren K.L., Rosen C.J., Turner R.T. Effects of parathyroid hormone (1-34) on tibia in an adult rat model for chronic alcohol abuse. Bone 2007, 40:1013-1020.
243. Silva M.J., Brodt M.D., Uthgenannt B.A. Morphological and mechanical properties of caudal vertebrae in the SAMP6 mouse model of senile osteoporosis. Bone 2004, 35:425-431.
244. Silver J., Yalcindag C., Sela-Brown A., Kilva R., Naveh-Many T. Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int. 1999, 56:S2-sS7.
245. Silverberg S.J., Shane E., Jacobs T.P., Siris E., Bilezikian J.P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 1999, 341:1249-1255.
246. Slovik D.M., Neer R.M., Potts J.T. Short-term effects of synthetic human parathyroid hormone-(1-34) administration on bone mineral metabolism in osteoporotic patients. J. Clin. Invest. 1981, 68:1261-1271.
247. Slovik D.M., Rosenthal D.I., Doppelt S., Potts J.T., Daly M.A., Campbell J.A., Neer R.M. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J. Bone Miner. Res. 1986, 1:377-381.
248. Sogaard C.H., Wronski T.J., McOsker J.E., Mosekilde L. The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology 1994, 134:650-657.
249. Sone T., Fukunaga M., Ono S., Nishiyama T. A small dose of human parathyroid hormone (1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Miner. Electrolyte Metab. 1995, 21:232-235.
250. Spurney R.F., Flannery P.J., Garner S.C., Athirakul K., Liu S., Guilak F., Quarles L.D. Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J. Clin. Invest. 2002, 109:1361-1371.
251. Stevenson M., Jones M.L., De Nigris E., Brewer N., Davis S., Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol. Assess. 2005, 9:1-160.
252. Tada K., Yamanuro T., Okumura H., Kasai R., Takahashi H. Restoration of axial and appendicular bone volumes by hPTH (1-34) in parathyroidectomized and osteopenic rats. Bone 1990, 11:163-169.
253. Takasu H., Bringhurst F.R. Type-1 parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptors activate phospholipase C in response to carboxyl-truncated analogs of PTH(1-34). Endocrinology 1998, 139:4293-4299.
254. Tam C.S., Heersche J.N.M., Murray T.M., Parsons J.A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration. Endocrinology 1981, 110:506-512.
255. Tashjian A.H., Chabner B.A. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J. Bone Miner. Res. 2002, 17:1151-1161.
256. Turner C.H. Biomechanics of bone: Determinants of skeletal fragility and bone quality. Osteoporos. Int. 2002, 13:97-104.
257. Tsai K.-S., Ebeling P.R., Riggs B.L. Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women. J. Clin. Endocrinol. Metab. 1989, 69:1024-1027.
258. Uusi-Rasi K., Semanick L.M., Zanchetta J.R., Bogado C.E., Eriksen E.F., Sato M., Beck T.J. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
259. Vahle J.L., Long G.G., Sandusky G., Westmore M., Ma Y.L., Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol. 2004, 32:426-438.
260. Vamvakas S., Bahner U., Heidland A. Cancer in end-stage renal disease: Potential factors involved. Am. J. Nephrol. 1998, 18:89-95.
261. Watson P.H., Lazowski D.A., Han V.K.M., Fraher L.J., Steer B.M., Hodsman A.B. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor-1 gene expression in ovariectomized rats. Bone 1995, 16:1-9.
262. Watson P.H., Fraher L.J., Hendy G.N., Chung U.I., Kisiel M., Natale B.V., Hodsman A.B. Nuclear localization of the type 1 PTH/PTHrP receptor in rat tissues. J. Bone Miner. Res. 2000, 15:1033-1044.
263. Watson P.H., Fraher L.J., Natak B.V., Kisiel M., Hendy G.N., Hodsman A.B. Nuclear localization of the type 1 parathyroid hormone/parathyroid hormone-related peptide receptor in MC3T3-E1 cells: Association with serum-induced cell proliferation. Bone 2000, 26:221-225.
264. Whitfield J.F., Morley P., Willick G.E., Ross V., Barbier J.-R., Isaacs R.J., Ohannessian-Barry L. Stimulation of growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH(1-31) (Ostabolin). Calcif. Tissue Int. 1996, 58:81-87.
265. Whitfield J.F., Morley P., Ross V., Preston E., Soska M., Barbier J.-R., Isaacs R.J., Maclean S., Ohannessian-Barry L., Willick G.E. The hypotensive actions of osteogenic and non-osteogenic parathyroid hormone (PTH) fragments. Calcif. Tissue Int. 1997, 60:302.
266. Whitfield J.F., Morley P., Langille P., Willick G.E. Adenyl cyclase-activating anabolic agents: parathyroid hormone and prostaglandin E. Anabolic Treatments for Osteoporosis 1998, 109-145. CRC Press, Boca Raton, FL. J.E. Whitfield, P. Morley (Eds.).
267. Whitfield J.F., Morley P., Fraher L., Hodsman A.B., Holdsworth D.W., Watson P.H., Willick G.E., Barbier J.R., Gulam M., Isaacs R.J., MacLean S., Ross V. The stimulation of vertebral and tibial bone growth by the parathyroid hormone fragments, hPTH-(1-31)NH2, [Leu27]cyclo(Glu22-Lys26)hPTH-(1-31)NH2, and hPTH-(1-30)NH2. Calcif. Tissue Int. 2000, 66:307-312.
268. Wronski T.J., Cintrón M., Dann L.M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif. Tissue Int. 1988, 43:179-183.
269. Wronski T.J., Dann L.M., Scott K.S., Cintrón M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcif. Tissue Int. 1989, 45:360-366.
270. Wronski T.J., Yen C.-F., Burton K.W., Mehta R.C., Newman P.S., Soltis E.E., DeLucca P.P. Skeletal effects of calcintonin in ovariectomized rats. Endocrinology 1991, 129:2246-2250.
271. Wronski T.J., Yen C.-F., Dann L.M. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 1993, 132:823-831.
272. Wronski T.J., Yen C.-F. Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 1994, 15:51-58.
273. Wu Y., Kumar R. Parathyroid hormone regulates transforming growth factor beta1 and beta2 synthesis in osteoblasts via divergent signaling pathways. J. Bone Miner. Res. 2000, 15:879-884.
274. Xiang A., Kanematsu M., Mitamura M., Kikkawa H., Asano S., Kinoshita M. Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice. Invest. Radiol. 2006, 41:704-712.
275. Yu X., Milas J., Watanabe N., Rao N., Murthy S., Potter O.L., Wenning M.J., Clapp W.D., Hock J.M. Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormone. Calcif. Tissue Int. 2006, 78:162-170.
276. Zanchetta J.R., Bogado C.E., Ferretti J.L., Wang O., Wilson M.G., Sato M., Gaich G.A., Dalsky G.P., Myers S.L. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J. Bone Miner. Res. 2003, 18:539-543.
277. Zhou H., Iida-Klein A., Lu S.S., Ducayen-Knowles M., Levine L.R., Dempster D.W., Lindsay R. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 2003, 32:513-520.